Stella Pharma's meningioma application heads to a Japanese drug panel, with a wider label than its trial tested
Japan's health ministry has said Stella Pharma's application to extend Steboronine to recurrent meningioma will go before a pharmaceutical affairs council committee, a review step rather than an approval, on a label wider than the high-grade patients in its trial.